Drug profile · INN
depemokimab
EXDENSUR
depemokimab (EXDENSUR) is a interleukin-5 inhibitor.
EMA: approved Respiratory system (R03) R03DX12
Patents linked 0
Pipeline programs 5
News articles 0
Drug details — depemokimab
- Class
- Respiratory system (R03)
- Route
- —
- Patents
- 0
- Programs
- 5
- Data quality
- 0.83
Quick answer
depemokimab (EXDENSUR) is a interleukin-5 inhibitor.
Key facts
INN depemokimab
Brand EXDENSUR
Mechanism Interleukin-5 inhibitor
Target Interleukin-5
Therapeutic class Respiratory system (R03)
ATC code R03DX12
Mechanism of action
Interleukin-5 inhibitor
Primary target: Interleukin-5
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is depemokimab?
depemokimab (EXDENSUR) is a interleukin-5 inhibitor.
What is the brand name for depemokimab?
EXDENSUR is a marketed brand name for depemokimab. Check FDA Drugs@FDA for the current US label holder and prescribing information.